Yonsei Cancer Center researchers have developed a three-drug combination that appears to be promising for patients with HER2-positive advanced gastric cancer who have failed first-line therapy. When compared to other therapies, this combination of HER2-targeted therapy trastuzumab, ramucirumab, and paclitaxel displayed higher effectiveness and fewer adverse effects. Because of the fast proliferation of cancer cells triggered by the receptor on their surface, HER2-positive gastric cancer has a bad prognosis. This form of cancer currently accounts for 10-15% of all advanced gastric cancers. The combination of trastuzumab and chemotherapy has dramatically boosted survival rates in first-line treatment. However, second-line therapeutic choices for individuals who have failed first-line therapy are limited. The study, led by Professor Rha Sun-young, had a 54% response rate overall.

To know more: About the original article click here.